Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
98 stopped studies mapped to Castration-Resistant Prostate Carcinoma and descendants · 100% state a reason
Over the 98 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04071236 | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation… | Phase 1 / Phase 2 | suspended | Aug 28, 2019 | National Cancer Institute (NCI) | Other - To assess the study's feasibility. | Other (stated, no rule matched) |
| NCT04615845 | A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC | Phase 1 | terminated | Nov 4, 2020 | Pharmicell Co., Ltd. | Difficulties in patient recruitment. | Enrollment / accrual |
| NCT03442556 | Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic… | Phase 2 | terminated | Feb 22, 2018 | University of Washington | Terminated due to insufficient funding | Funding |
| NCT04631601 | Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer… | Phase 1 / Phase 2 | terminated | Nov 17, 2020 | Amgen | Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not… | Safety / toxicity |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | Phase 1 / Phase 2 | terminated | Jul 15, 2019 | Memorial Sloan Kettering Cancer Center | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT06200103 | Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate… | Phase 2 | suspended | Jan 10, 2024 | Mayo Clinic | Pending additional funding. | Funding |
| NCT05689021 | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate… | Phase 2 | terminated | Jan 18, 2023 | Mayo Clinic | Sponsor decided to close due to slow accrual and lack of efficacy | Efficacy / futility |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients… | Phase 1 / Phase 2 | withdrawn | May 6, 2026 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT03437941 | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients… | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Corcept Therapeutics | The level of benefit observed did not justify enrolling patients in the Dose Expansion phase of the… | Enrollment / accrual |
| NCT04716725 | 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer | Phase 2 | terminated | Jan 20, 2021 | Thomas Hope | Low accrual | Enrollment / accrual |
| NCT07025512 | 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone… | Phase 2 | withdrawn | Jun 17, 2025 | M.D. Anderson Cancer Center | PI requested | Other (stated, no rule matched) |
| NCT07052760 | Imaging of Solid Tumors Using DLL3 SPECT | Early Phase 1 | withdrawn | Jul 7, 2025 | Thomas Hope | Sponsor funding | Funding |
| NCT05588609 | Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers | Phase 2 | terminated | Oct 20, 2022 | Partner Therapeutics, Inc. | Merus terminated the study early due to changes in organizational priorities. | Other (stated, no rule matched) |
| NCT02555189 | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant,… | Phase 1 / Phase 2 | terminated | Sep 21, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Sponsor-PI decision. An analysis of the primary endpoint concluded that the addition of ribociclib… | Other (stated, no rule matched) |
| NCT03869762 | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant…(DICE) | Phase 2 | terminated | Mar 11, 2019 | Cancer Trials Ireland | Insufficient accrual | Enrollment / accrual |
| NCT04853498 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets | Phase 1 | terminated | Apr 21, 2021 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns. | Safety / toxicity |
| NCT03360721 | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic… | Phase 2 | terminated | Dec 4, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04179864 | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With…(CELLO-1) | Phase 1 / Phase 2 | terminated | Nov 27, 2019 | Epizyme, Inc. | The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in… | Safety / toxicity |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT02744287 | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With… | Phase 1 | terminated | Apr 20, 2016 | Regeneron Pharmaceuticals | Due to a Dose Limiting Toxicity. | Safety / toxicity |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Feb 15, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT01995058 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With… | Phase 2 | terminated | Nov 26, 2013 | Exelixis | Sponsor decided to close the study prior to completion of enrollment. This was a business decision… | Safety / toxicity |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT05037500 | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate… | Phase 1 | terminated | Sep 8, 2021 | Roswell Park Cancer Institute | PI closed study | Other (stated, no rule matched) |
| NCT03792841 | Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC | Phase 1 | terminated | Jan 3, 2019 | Amgen | Sponsor Decision | Sponsor / business decision |
| NCT04616547 | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy… | Phase 2 | terminated | Nov 5, 2020 | National Cancer Institute (NCI) | Insufficient drug supply | Drug supply |
| NCT05369000 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant… | Phase 1 | terminated | May 11, 2022 | Lava Therapeutics | The trial was intended to be a Phase 1/2 trial (but the trial never moved forward to Phase 2). | Other (stated, no rule matched) |
| NCT03815942 | VAccination in Early and ADvanced Prostate caNCEr(ADVANCE) | Phase 1 / Phase 2 | terminated | Jan 24, 2019 | University of Oxford | COVID stopped all trials - and ADVANCE could not restart again after the pandemic | COVID-19 / pandemic |
| NCT04102124 | A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC | Phase 2 | terminated | Sep 25, 2019 | Jiangsu HengRui Medicine Co., Ltd. | The sponsor's R\&D strategy is adjusted. | Sponsor / business decision |
| NCT04740034 | A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma | Phase 1 | terminated | Feb 5, 2021 | Amgen | Sponsor strategic decision | Sponsor / business decision |
| NCT04927663 | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | Phase 1 | terminated | Jun 16, 2021 | Rahul Aggarwal | Slow accrual | Enrollment / accrual |
| NCT05177770 | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With… | Phase 2 | terminated | Jan 5, 2022 | Coherus Oncology, Inc. | The study was terminated for strategic reasons, not due to any safety concerns. | Safety / toxicity |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With… | Phase 1 / Phase 2 | terminated | Sep 21, 2020 | Opna Bio LLC | study terminated due to business realignment | Sponsor / business decision |
| NCT05208229 | The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium -…(WB-LuPSMA) | — | terminated | Jan 26, 2022 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | The study was linked to another protocol that is over | Other (stated, no rule matched) |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant… | Phase 1 | terminated | Jan 31, 2020 | Poseida Therapeutics, Inc. | Study closed | Other (stated, no rule matched) |
| NCT05241613 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Feb 16, 2022 | Accutar Biotechnology Inc | Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study | Other (stated, no rule matched) |
| NCT05501548 | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant… | Phase 2 | terminated | Aug 15, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study was terminated by the IRB due to low accrual, | Enrollment / accrual |
| NCT04951492 | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | Phase 2 | terminated | Jul 6, 2021 | University of Washington | Withdrawal of funding | Funding |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT05917470 | A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate… | Phase 1 / Phase 2 | terminated | Jun 23, 2023 | Oncternal Therapeutics, Inc | Oncternal Therapeutics, Inc. announced on 12 SEP 2024 its decision to discontinue its clinical… | Other (stated, no rule matched) |
| NCT05156905 | Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Dec 14, 2021 | University of California, San Diego | Oncternal closing clinical trial operations. | Other (stated, no rule matched) |
| NCT03177187 | Combination Study of AZD5069 and Enzalutamide.(ACE) | Phase 1 / Phase 2 | terminated | Jun 6, 2017 | Institute of Cancer Research, United Kingdom | Discontinuation of production of IMP | Other (stated, no rule matched) |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | Phase 1 / Phase 2 | withdrawn | Mar 26, 2024 | Baptist Health South Florida | Funding for the study was withdrawn. | Funding |
| NCT03850795 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 | terminated | Feb 22, 2019 | Hinova Pharmaceuticals USA, Inc. | Terminated by Sponsor for various factors including prolonged duration and enrollment challenges | Enrollment / accrual |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally… | Phase 1 | terminated | Oct 20, 2021 | Biosplice Therapeutics, Inc. | Study was terminated due business reasons by Sponsor. | Sponsor / business decision |
| NCT04629781 | Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in… | Phase 1 | terminated | Nov 16, 2020 | Swiss Cancer Institute | SAKK decided to premature terminate this trial as additional follow-up visits do not further… | Efficacy / futility |
| NCT04159896 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 2 | terminated | Nov 12, 2019 | Barbara Ann Karmanos Cancer Institute | The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA… | Safety / toxicity |
| NCT03770455 | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | Phase 2 | terminated | Dec 10, 2018 | Jodi Layton, MD | Early signs of progression and learned experience that the assumed time period between psa… | Other (stated, no rule matched) |
| NCT03690141 | An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced… | Phase 2 | terminated | Oct 1, 2018 | Effector Therapeutics | Terminated early due to a lack of efficacy. | Efficacy / futility |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials